American Society of Clinical Oncology

SHERPA: White

People

  1. Motzer
    Motzer
  2. Scher
    Scher
  3. O'Reilly
    O'Reilly
  4. Saltz
    Saltz
  5. Bajorin
    Bajorin
  6. Kris
    Kris
  7. Hudis
    Hudis
  8. Morris
    Morris
  9. Rosenberg
    Rosenberg
  10. Robson
    Robson

Groups

  1. Department of Medicine (6399)
  2. Solid Tumor Oncology Division (5537)
  3. Survivorship Research (1997)
  4. Genitourinary Oncology Service (1768)
  5. Surgery (1637)
  6. Epidemiology and Biostatistics (1495)
  7. GSK Faculty (1389)
  8. Population Sciences Research Program (1379)
  9. Gastrointestinal Oncology Service (1353)
  10. Hematologic Malignancies, Division of (1281)
Search Within
Formats
  1. Meeting Abstract (6334)
  2. Journal Article (2579)
  3. Editorial (76)
  4. Review (68)
  5. Guidelines (54)
  6. Correspondence (49)
  7. Miscellaneous (4)
  8. Conference Paper (3)
Groups
  1. Department of Medicine (6399)
  2. Solid Tumor Oncology Division (5537)
  3. Survivorship Research (1997)
  4. Genitourinary Oncology Service (1768)
  5. Surgery (1637)
  6. Epidemiology and Biostatistics (1495)

More Groups

People
  1. Robert Motzer (451)
  2. Howard Scher (334)
  3. Eileen O'Reilly (306)
  4. Leonard Saltz (283)
  5. Dean Bajorin (280)
  6. Mark Kris (253)

More People

Years
  1. 2025 (275)
  2. 2024 (554)
  3. 2023 (580)
  4. 2022 (554)
  5. 2021 (504)
  6. 2020 (539)

More Years

Publications
  1. Journal of Clinical Oncology (8694)
  2. JCO Precision Oncology (171)
  3. Journal of Oncology Practice (124)
  4. American Society of Clinical Oncology Educational Book (112)
  5. JCO Clinical Cancer Informatics (53)
  6. JCO Oncology Practice (7)

More Publications

Results (9167)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Efficacy and safety of olomorasib (LY3537982), a second-generation KRAS G12C inhibitor (G12Ci), in combination with pembrolizumab in patients with KRAS G12C-mutant advanced NSCLC
    Meeting Abstract

    Burns, T. F.; Dragnev, K. H.; Fujiwara, Y.; Murciano-Goroff, Y. R.; Lee, D. H.; Hollebecque, A.; Koyama, T.; Cassier, P. A.; Italiano, A.; Heist, R. S.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Correlative results from NCI CTEP/ETCTN 10330: A phase 2 study of belinostat with SGI-110 (guadecitabine) or ASTX727 (decitabine/cedazuridine) for advanced conventional chondrosarcoma (cCS)
    Meeting Abstract

    Lacuna, K. P.; Ingham, M.; Chen, L.; Das, B.; Lee, S. M.; Ge, L.; Druta, M.; Conley, A. P.; Keohan, M. L.; Agulnik, M.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Phase 3 dose selection for selinexor in TP53wt endometrial cancer based on exposure-response analysis
    Meeting Abstract

    Makker, V.; Richardson, D. L.; Chon, H. S.; Miller, D. S.; Mau-Sorensen, M.; Cibula, D.; Zagouri, F.; Fidalgo, A. P.; Slomovitz, B. M.; Coleman, R. L.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Benefit of rituximab maintenance after first-line bendamustine-rituximab in mantle cell lymphoma
    Meeting Abstract

    Wang, Y.; Larson, M. C.; Kumar, A.; Hill, B. T.; Bond, D. A.; Kahl, B. S.; Danilov, A. V.; Merryman, R.; Grover, N. S.; Tun, A. M.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Ponatinib (PON) in patients (pts) with chronic-phase chronic myeloid leukemia (CP-CML) and the T315I mutation (mut): 4-year results from OPTIC
    Meeting Abstract

    Deininger, M.; Apperley, J.; Arthur, C. K.; Chuah, C.; Hochhaus, A.; de Lavallade, H.; Lipton, J. H.; Lomaia, E.; McCloskey, J. K.; Maness, L. J.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Dose-expansion part of a phase 1b global study of E7386 in combination with lenvatinib (LEN) in patients (pts) with hepatocellular carcinoma (HCC) and other solid tumors including endometrial cancer (EC)
    Meeting Abstract

    Lee, J. Y.; Ryoo, B. Y.; Kim, J. W.; Cheng, A. L.; Finn, R. S.; Hasegawa, K.; Makker, V.; Kudo, M.; Miller, D. S.; Merle, P.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Pan-tumor activity of olomorasib (LY3537982), a second-generation KRAS G12C inhibitor (G12Ci), in patients with KRAS G12C-mutant advanced solid tumors
    Meeting Abstract

    Heist, R. S.; Koyama, T.; Murciano-Goroff, Y. R.; Hollebecque, A.; Cassier, P. A.; Han, J. Y.; Tosi, D.; Sacher, A. G.; Burns, T. F.; Spira, A. I.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Alectinib in pediatric patients with solid or CNS tumors harboring ALK-fusions: Emerging pharmacokinetic data from the iMATRIX alectinib phase I/II open-label, multi-center study
    Meeting Abstract

    Doz, F.; Casanova, M.; Koh, K. N.; Nysom, K.; Canete, A.; Kang, H. J.; Karajannis, M. A.; Hargrave, D. R.; Corradini, N.; Wu, Y.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Lisocabtagene maraleucel (liso-cel) in patients (pt) with R/R mantle cell lymphoma (MCL): Subgroup analyses by number of prior systemic lines of therapy (LOT) and by response to prior Bruton tyrosine kinase inhibitor (BTKi) from the TRANSCEND NHL 001 MCL cohort (TRANSCEND-MCL)
    Meeting Abstract

    Palomba, M. L.; Siddiqi, T.; Gordon, L. I.; Kamdar, M. K.; Lunning, M. A.; Hirayama, A. V.; Abramson, J. S.; Arnason, J.; Ghosh, N.; Mehta, A.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Efficacy and safety of erdafitinib in pediatric patients with advanced solid tumors and FGFR alterations in the phase 2 RAGNAR trial
    Meeting Abstract

    Witt, O.; Sait, S. F.; Diez, B. D.; Cardoso, A.; Reardon, D. A.; Welsh, L.; Shih, K. C.; Baldini, C.; Massard, C.; Loriot, Y.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save